IA
EGRX

IFP Advisors’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

IFP Advisors’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-14
Closed -$3K – 4881
2022
Q3 		$3K Buy
14
+2
+17% +$73 ﹤0.01% 4286
2022
Q2 		$3K Hold
12
– – ﹤0.01% 4050
2022
Q1 		$3K Buy
+12
New +$576 ﹤0.01% 4050
2016
Q1 		– Sell
-50
Closed -$4K – 3537
2015
Q4 		$4K Buy
+50
New +$3.95K ﹤0.01% 3110

Other funds holding EGRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
SGCIA
Smith Graham & Co Investment Advisors Houston, Texas $868M AUM 24.69% 1-Year Est. Return

IFP Advisors's EGRX Position: Q4 2022 in Review

IFP Advisors sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q4 2022, closing a stake of 14 shares — an estimated $3K sold.

IFP Advisors first reported a position in EGRX in Q4 2015 and held it in 4 quarters. The position peaked at $4K in Q4 2015. 152 funds tracked by Wall St. Rank hold EGRX as of Q4 2022.

  • IFP Advisors reported no remaining Eagle Pharmaceuticals, Inc. position as of Q4 2022 after selling out during the quarter.
  • IFP Advisors sold 14 Eagle Pharmaceuticals, Inc. shares in Q4 2022, an estimated $3K.
  • IFP Advisors first reported a position in Eagle Pharmaceuticals, Inc. in Q4 2015 and held it in 4 quarters.
  • IFP Advisors's Eagle Pharmaceuticals, Inc. position peaked at $4K in Q4 2015.
  • 152 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q4 2022.

Based on IFP Advisors's 13F filing for Q4 2022, filed 7 Feb 2023.